Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis

  • Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2
  • 62% of patients treated with ianalumab plus eltrombopag achieved sustained platelet response at six months compared to 39% with placebo plus eltrombopag1,2
/by

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
arcticnovartis

  • Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2
  • 62% of patients treated with ianalumab plus eltrombopag achieved sustained platelet response at six months compared to 39% with placebo plus eltrombopag1,2
/by

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis

  • Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1
  • KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12
  • New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13
/by

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis

  • Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1
  • KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12
  • New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13
/by

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
arcticnovartis

  • Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1
  • KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all Phase III trials2-12
  • New NATALEE 5-year sub-analysis data reinforce sustained reduction in distant disease-free survival in broadest population of EBC patients13
/by

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS

Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
arcticnovartis

  • Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker
  • Scemblix data across clinical and real-world settings offer new evidence informing CML care amid evolving patient needs
  • 96-week pelabresib Phase III data represent longest follow-up of first-line myelofibrosis patients in randomized combination trial
/by

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis announces plans to build flagship manufacturing hub in North Carolina

Novartis announces plans to build flagship manufacturing hub in North Carolina
arcticnovartis

  • Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030
  • Enables manufacturing of medicines across company’s main therapeutic areas in one geographic location
/by